PURPOSE: The aim of this study was to estimate 201Tl SPECT and CT-MRI cut-off values that lead to a validated prognostic classification for the end-point overall survival, in order to discriminate glioma patients with good and poor prognosis at an early stage during chemotherapeutic treatment. METHODS: We studied patients who underwent 201Tl SPECT and CT-MRI before and after two courses of chemotherapy. Cut-off values were retrieved from the Cox model. Patients were classified according to the computed cut-off values, creating subgroups of patients with different prognosis in terms of survival [tumour regression (TR); stable disease (SD); tumour progression (TP)]. The differences between the subgroups were assessed by Kaplan-Meier analyses. The predictive performance of the classification procedure was evaluated by a leave-one-out cross-validation method. RESULTS: 201Tl SPECT classified 41% of the patients as SD, 25% as TR and 34% as TP. CT-MRI classified 82% of the patients as SD, and only 4% and 14% as TR and TP, respectively. Of those patients with a relatively long overall survival (i.e. > or =16 months), cross-validation estimates of 201Tl SPECT classification rates were 50% TR and 50% SD, and cross-validation estimates of CT-MRI classification rates were 7% TR, 72% SD, and 21% TP. CONCLUSION: We constructed a 201Tl SPECT model that makes it possible to identify glioma patients with a good or a poor prognosis at an early stage during chemotherapeutic treatment. With this model, accurate predictions can be made with regard to the expected duration of survival.
PURPOSE: The aim of this study was to estimate 201Tl SPECT and CT-MRI cut-off values that lead to a validated prognostic classification for the end-point overall survival, in order to discriminate gliomapatients with good and poor prognosis at an early stage during chemotherapeutic treatment. METHODS: We studied patients who underwent 201Tl SPECT and CT-MRI before and after two courses of chemotherapy. Cut-off values were retrieved from the Cox model. Patients were classified according to the computed cut-off values, creating subgroups of patients with different prognosis in terms of survival [tumour regression (TR); stable disease (SD); tumour progression (TP)]. The differences between the subgroups were assessed by Kaplan-Meier analyses. The predictive performance of the classification procedure was evaluated by a leave-one-out cross-validation method. RESULTS: 201Tl SPECT classified 41% of the patients as SD, 25% as TR and 34% as TP. CT-MRI classified 82% of the patients as SD, and only 4% and 14% as TR and TP, respectively. Of those patients with a relatively long overall survival (i.e. > or =16 months), cross-validation estimates of 201Tl SPECT classification rates were 50% TR and 50% SD, and cross-validation estimates of CT-MRI classification rates were 7% TR, 72% SD, and 21% TP. CONCLUSION: We constructed a 201Tl SPECT model that makes it possible to identify gliomapatients with a good or a poor prognosis at an early stage during chemotherapeutic treatment. With this model, accurate predictions can be made with regard to the expected duration of survival.
Authors: Ban Tony; Maaike J Vos; Johannes Berkhof; Tjeerd J Postma; Arthur van Lingen; Jan J Heimans; Otto S Hoekstra Journal: Nucl Med Commun Date: 2005-01 Impact factor: 1.690
Authors: Manuel Gómez-Río; Dolores Martínez Del Valle Torres; Antonio Rodríguez-Fernández; José Manuel Llamas-Elvira; Simeón Ortega Lozano; Carlos Ramos Font; Escarlata López Ramírez; Majed Katati Journal: Eur J Nucl Med Mol Imaging Date: 2004-05-06 Impact factor: 9.236
Authors: W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch Journal: J Natl Cancer Inst Date: 1993-05-05 Impact factor: 13.506
Authors: Maaike J Vos; Johannes Berkhof; Otto S Hoekstra; Ingeborg Bosma; Eefje M Sizoo; Jan J Heimans; Jaap C Reijneveld; Esther Sanchez; Frank J Lagerwaard; Jan Buter; David P Noske; Tjeerd J Postma Journal: Neuroradiology Date: 2011-07-14 Impact factor: 2.804
Authors: Manuel Gómez-Río; Antonio Rodríguez-Fernández; Carlos Ramos-Font; Escarlata López-Ramírez; José Manuel Llamas-Elvira Journal: Eur J Nucl Med Mol Imaging Date: 2008-01-03 Impact factor: 9.236